Harms

AT Amytis Towfighi
EC Eric M. Cheng
MA Monica Ayala-Rivera
HM Heather McCreath
NS Nerses Sanossian
TD Tara Dutta
BM Bijal Mehta
RB Robert Bryg
NR Neal Rao
SS Shlee Song
AR Ali Razmara
MR Magaly Ramirez
TS Theresa Sivers-Teixeira
JT Jamie Tran
EM Elizabeth Mojarro-Huang
AM Ana Montoya
MC Marilyn Corrales
BM Beatrice Martinez
PW Phyllis Willis
MM Mireya Macias
NI Nancy Ibrahim
SW Shinyi Wu
JW Jeremy Wacksman
HH Hilary Haber
AR Adam Richards
FB Frances Barry
VH Valerie Hill
BM Brian Mittman
WC William Cunningham
HL Honghu Liu
DG David A. Ganz
DF Diane Factor
BV Barbara G. Vickrey
request Request a Protocol
ask Ask a question
Favorite

Adverse experiences are reported as required by the IRB at each site. There are no additional US Food and Drug Administration regulations because we are not studying a biological agent. The Manual of Operations includes detailed definitions of adverse experiences, a table for grading their severity, and details of how clinical sites are to report them.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

0/150

tip Tips for asking effective questions

+ Description

Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.

post Post a Question
0 Q&A